No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety ...
Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular lymphoma, a disease that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback